Circulating biomarkers, assessed by ELISA, demonstrated that higher levels of PD-1 and PD-L1 were associated with the upregulation of IFN-gamma and IL-10 (p < 0.05); patients with a high tumor expression of PD-1 showed higher serum levels of IFN-gamma and IL-10, but plasma PD-L1 did not correlate with tumor PD-L1 expression. This evidence concerns the gene IL10 and neoplasm.